• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah

    4/9/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email

    Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more

    SALT LAKE CITY, April 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company executives will be participating in the latest World Trade Center (WTC) Utah trade mission with Utah Governor Cox and the Governor's Office of Economic Opportunity, taking place April 13-22 in locations across Switzerland and Germany.

    (PRNewsfoto/Co-Diagnostics)

    "Switzerland and Germany are home to many of the world's leading technology, diagnostics, financial and R&D environments," said Dwight Egan, Chief Executive Officer, Co-Diagnostics, Inc. "We are pleased to be part of this prestigious trade mission and to help further the goals of our community, while strengthening our own international network of strategic partners and advancing important Co-Dx initiatives."

    WTC Utah anticipates that the mission will reinforce connections and deepen commercial, diplomatic, and institutional ties in two of Europe's most influential economies. The itinerary is planned to include visits at notable academic and research institutions, as well as networking events and site visits with globally recognized industry leaders like Union Bank of Switzerland ("UBS") and Roche Diagnostics, one of the world's foremost providers of diagnostics systems.

    Company executives are expected to largely participate in the Switzerland portion of the trade mission, before traveling to Munich to meet with prospective customers and distributors at the Congress of the European Society of Clinical Microbiology and Infectious Disease ("ESCMID Global") 2026 in Munich, Germany.

    The WTC trade mission comes as Co-Dx is reinforcing global relationships in preparation for introducing a real-time PCR point-of-care diagnostic platform, currently preparing for a 510(k) submission to the U.S. Food & Drug Administration, and follows recent announcements related to the Company's international joint ventures in India and the Kingdom of Saudi Arabia.

    World Trade Center Utah is the official international business promotion organization for the Governor's Office of Economic Opportunity in the State of Utah and conducts important trade missions around the world, connecting Utah business to global resources.

    *The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

    About Co-Diagnostics, Inc.:

    Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-executives-to-participate-in-european-trade-mission-with-utah-governor-and-wtc-utah-302737703.html

    SOURCE Co-Diagnostics

    Get the next $CODX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:04:45 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:04:12 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    President Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:03:48 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.

    SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)

    6/3/26 4:22:01 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Co-Diagnostics Inc.

    EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)

    6/1/26 12:15:03 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Co-Diagnostics Inc.

    S-3 - Co-Diagnostics, Inc. (0001692415) (Filer)

    5/28/26 4:30:41 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Co-Diagnostics downgraded by Sidoti with a new price target

    Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

    8/12/22 9:07:51 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Sidoti initiated coverage on Co-Diagnostics with a new price target

    Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

    12/29/21 8:45:34 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

    HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

    11/12/21 6:13:11 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States

    Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its mosquito abatement district ("MAD") customer base for the Vector Smart® line of products and services have grown to include MADs in 21 states, with four new full laboratory installs added in June alone. The announcement coincides with Co-Dx hosting a webinar for prospective MAD customers in recognition

    6/25/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line

    Visit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer SALT LAKE CITY, June 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that a delegation from CoMira Diagnostics ("CoMira"), the Company's joint venture with partners in the Kingdom of Saudi Arabia ("KSA"), visited Co-Diagnostics' Salt Lake City headquarters ahead of a planned technology transfer to CoMira. The visit included a tour of the Company's facilities and unveiling a future automated manufacturing

    6/18/26 9:05:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement

    Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American marketSALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into an exclusive distribution agreement with its longstanding partner in Mexico for the Co-Dx™ PCR point-of-care platform*, including the PCR Pro® instrument and associated test kits, advancing the Company's strategy to expand its commercialization network and footprin

    6/11/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

    SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

    4/4/24 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

    SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

    8/29/23 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

    SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf

    11/1/22 9:32:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Financials

    Live finance-specific insights

    View All

    Co-Diagnostics Reports First Quarter 2026 Financial Results

    Advancing Global Commercialization Through CoSara Regulatory Progress and Regional ExpansionExecuting Clinical Strategy with Upper Respiratory Submission Preparation and TB Study InitiationExpanding International Presence and Reinforcing Platform Differentiation Through Partnerships and IPSALT LAKE CITY, May 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the first quarter ended March 31, 2026.

    5/14/26 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast

    SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    4/30/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Reports Full Year 2025 Financial Results

    Advancing Global Commercialization Strategy Through CoSara and CoMira Joint VenturesProgressing Clinical Pipeline and Regulatory Pathways for PCR PlatformStrengthening Technology Leadership with AI Integration and Expanding IP PortfolioSALT LAKE CITY, March 31, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financia

    3/31/26 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/13/24 5:02:32 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/9/22 3:43:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    7/12/21 8:29:19 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care